Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FluoroPharma, a developer of molecular imaging agents, has announced that the US Patent and Trademark Office has issued new US patent, covering methods of imaging cardiovascular plaque formation using F18 labeled 2-fluorodeoxy-D-glucose.
Subscribe to our email newsletter
This patent, exclusively licensed from the Massachusetts General Hospital, provides FluoroPharma with additional patent claims that cover imaging of atherosclerotic plaque inflammation and rupture.
Kundakovic, president of FluoroPharma, said: “Our broad technology platform continues to provide FluoroPharma with the ability to develop effective cardiovascular imaging agents for PET market.”